Literature DB >> 12726729

Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release.

Stephan Bour1, Hirofumi Akari, Eri Miyagi, Klaus Strebel.   

Abstract

The envelope glycoprotein of HIV-2 ROD10 has the intriguing ability to enhance the rate of viral particle release from infected cells. However, not all HIV-2 envelope glycoproteins are active in this regard. Indeed, we have previously noted that, despite a high degree of identity with that of ROD10, the envelope protein of the ROD14 isolate was unable to enhance virus production. In this study, site-directed mutagenesis was employed to reveal that a single naturally occurring alanine-to-threonine substitution at position 598, located in the extracellular part of the TM subunit, fully accounted for the lack of activity of the ROD14 Env in HeLa and 12D7 cells. A second mutation at position 422, substituting a lysine residue in ROD10 for an arginine in ROD14, was additionally required for efficient virus release from infected H9 cells, suggesting cell-type-specific requirements for this activity. Interestingly, the ROD14 Env protein exhibited a trans-dominant negative effect on particle release by ROD10 Env, suggesting that the viral release activity of the HIV-2 ROD envelope protein may be regulated by its ability to assemble into functional oligomeric structures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12726729     DOI: 10.1016/s0042-6822(02)00128-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

Review 1.  The restriction factors of human immunodeficiency virus.

Authors:  Reuben S Harris; Judd F Hultquist; David T Evans
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

2.  Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Authors:  Lisa A Lopez; Su Jung Yang; Heiko Hauser; Colin M Exline; Kevin G Haworth; Jill Oldenburg; Paula M Cannon
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 3.  BST-2/tetherin: a new component of the innate immune response to enveloped viruses.

Authors:  David T Evans; Ruth Serra-Moreno; Rajendra K Singh; John C Guatelli
Journal:  Trends Microbiol       Date:  2010-08-03       Impact factor: 17.079

4.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

5.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.

Authors:  Vasundhara Varthakavi; Rita M Smith; Stephan P Bour; Klaus Strebel; Paul Spearman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

6.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Authors:  Heiko Hauser; Lisa A Lopez; Su Jung Yang; Jill E Oldenburg; Colin M Exline; John C Guatelli; Paula M Cannon
Journal:  Retrovirology       Date:  2010-06-07       Impact factor: 4.602

Review 7.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

Review 8.  The great escape: viral strategies to counter BST-2/tetherin.

Authors:  Janet L Douglas; Jean K Gustin; Kasinath Viswanathan; Mandana Mansouri; Ashlee V Moses; Klaus Früh
Journal:  PLoS Pathog       Date:  2010-05-13       Impact factor: 6.823

Review 9.  Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.

Authors:  Andrey Tokarev; Mark Skasko; Kathleen Fitzpatrick; John Guatelli
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

10.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.